韓国の急性冠動脈症候群患者の臨床的に有意な出血 侵襲的管理のためのランダム化臨床試験
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。急性冠動脈症候群の韓国人患者におけるチカグレロの使用は,クロピドグレルと比較して著しく多くの出血事件を引き起こしました. 効果の評価は有意に異なることはなかったが,この研究は確認には不十分であった.
科学分野
- 心臓病科
- 薬理学について
- 臨床試験
背景
- 東アジアの集団における強力なP2Y12阻害剤であるチカグレロルの安全性と有効性は,異なる出血および不血症の危険性のために不確実である.
- この不確実性は,抗血小板治療を受けている多様な民族集団における特定の調査を必要とします.
研究 の 目的
- 韓国の急性冠動脈症候群 (ACS) 患者におけるチカグレロの安全性と有効性を,クロピドグレルと比較して評価する.
- この特定の集団における臨床的に有意な出血および不血症の発生率を評価する.
主な方法
- 800人の韓国人のACS患者で,ランダムにチカグレロまたはクロピドグレルを投与したマルチセンター試験.
- 臨床的に有意な出血は,PLATO基準で定義され,12ヶ月間評価された.
- 投与された抗血小板剤の標準的な充填量と維持用量を投与した.
主要な成果
- クリニック的に有意な出血は,クロピドグレル (5. 3%) よりもチカグレル (11. 7%) で有意に多く発生しました (HR,2.26;P=0. 002).
- 重度の出血 (7. 5% 対 4. 1%) と致死性出血 (1% 対 0%) もチカグレロール群では高かった.
- 心血管疾患による死亡,心筋梗塞,脳卒中の複合的な差は認められなかった (9. 2% vs 5. 8%; P=0. 07).
結論
- 標準投与のチカグレロは,クロピドグレルと比較して,韓国人のACS患者で臨床的に有意な出血の発生率と関連していました.
- 臨床試験の有効性に関する結論は,試験の設計が不十分であるため,チカグレロールの有血病発生率が数値的に高いため,慎重に解釈する必要があります.
関連する概念動画
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...